Abstract: The present invention relates to a method for the production of sodium bicarbonate, particularly for producing sodium bicarbonate on an industrial scale, the method comprising the steps of: a. treating a carbonaceous feedstock to form a product stream comprising up to 10 v/v % carbon dioxide; b. capturing at least a portion of the carbon dioxide from the product stream to form a carbon dioxide stream; c. feeding the carbon dioxide stream to a reaction vessel; d. feeding an aqueous sodium carbonate solution to the reaction vessel; e. contacting at least a portion of the carbon dioxide stream with at least a portion of the aqueous sodium carbonate solution to form a slurry comprising solid sodium bicarbonate; and f. separating the solid component of the slurry from the liquid component of the slurry to provide solid sodium bicarbonate and an aqueous liquor.

Abstract: The present invention relates to a method for the production of sodium bicarbonate, particularly for producing sodium bicarbonate on an industrial scale, the method comprising the steps of: a. treating a carbonaceous feedstock to form a product stream comprising up to 10 v/v % carbon dioxide; b. capturing at least a portion of the carbon dioxide from the product stream to form a carbon dioxide stream; c. feeding the carbon dioxide stream to a reaction vessel; d. feeding an aqueous sodium carbonate solution to the reaction vessel; e. contacting at least a portion of the carbon dioxide stream with at least a portion of the aqueous sodium carbonate solution to form a slurry comprising solid sodium bicarbonate; and f. separating the solid component of the slurry from the liquid component of the slurry to provide solid sodium bicarbonate and an aqueous liquor.

Abstract: Certain embodiments are directed to methods for treating Ewing family tumors (EFT) comprising administering an effective amount of altertoxin II to a subject having EFT.

Abstract: Certain embodiments are directed to methods for treating Ewing family tumors (EFT) comprising administering an effective amount of altertoxin II to a subject having EFT.

Abstract: A wire fabrication apparatus includes a number of fluid channels, each fluid channel configured to receive a first portion of a corresponding wire of a number of wires and including a fluid flowing in a first direction therein. A twisting mechanism is configured for attachment to second portions of the number of wires, the twisting mechanism being configured to draw the number of wires from the number of fluid channels in a second direction opposite to the first direction and to twist the number of drawn wires. A controller controls twisting mechanism to form a twisted wire, including controlling the twisting mechanism to draw the number of wires from the number of fluid channels in the second direction and to twist the drawn wire.

Abstract: A method includes attaching a micro-coaxial wire to electrical contacts in a substrate, the micro-coaxial wire including a core wire, a bonded section, and a shield layer, the electrical contacts including a first electrical contact and a second electrical contact. Attaching the micro-coaxial wire to the electrical contacts includes connecting a core wire of the micro-coaxial wire to the first electrical contact including forming a bonded section by bonding the core wire to the first electrical contact, and then depositing solder onto the bonded section of the core wire.

Abstract: The invention provides compositions and methods that modulate the activity of AKT family kinase proteins, including AKT1, AKT2 and AKT3 (also referred to as PKB?, PKB?and PKB?). Specifically, the invention provides a number of phenoxazine and acridone compounds that inhibit AKT phosphorylation and kinase activity. The invention provides compositions for and methods of modulating AKT activity, inhibiting cell growth, treating cancer, treating transplant rejection, and treating coronary artery disease based upon the phenoxazine and acridone compounds of the invention.

Abstract: The present invention relates to the use of imatinib of the following formula or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of a cancer that expresses breast cancer resistant protein (BCRP) in a human subject in need of such a treatment.

Abstract: A process for the direct crystallization of a compound of the formula I: or a pharmaceutically acceptable salt thereof, is disclosed, wherein R1 and R2 represent H, C1-10 alkyl, aryl or heteroaryl, or substituted C1-10 alkyl, aryl or heteroaryl and X+ represents a charge balancing group, comprising extracting a solution containing a crude compound of formula I or Ia: or a pharmaceutically acceptable salt thereof, wherein each X+ is a charge balancing group, and R1 and R2 are as described above with a C4-10 alcohol, collecting and crystallizing the resulting aqueous phase to produce a crystalline compound of formula I.

Abstract: The present invention is directed to a novel process for the preparation of the compound N-[1(R)-[(1,2-dihydro-1-methanesulfonyl-spiro[3H-indole-3,4'-piperdin]-1'- yl)carbonyl]-2-(phenylmethyl-oxy)ethyl]-2-amino-2-methyl-propanamide, and salts thereof, which has the structure: ##STR1## and which has the ability to stimulate the release of natural or endogenous growth hormone. This compound may be used to treat conditions which require the stimulation of growth hormone production or secretion such as in humans with a deficiency of natural growth hormone or in animals used for food or wool production where the stimulation of growth hormone will result in a larger, more productive animal.